©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Apr 26, 2017; 5(2): 63-70
Published online Apr 26, 2017. doi: 10.13105/wjma.v5.i2.63
Published online Apr 26, 2017. doi: 10.13105/wjma.v5.i2.63
Mucin expression and the pancreas: A systematic review and meta-analysis
Yaron Niv, Department of Gastroenterology, Rabin Medical Center, Tel Aviv University, Petach Tikva 4910000, Israel
Author contributions: Niv Y solely contributed to this paper.
Conflict-of-interest statement: None.
Data sharing statement: None.
Correspondence to: Yaron Niv, MD, FACG, AGAF, Professor, Department of Gastroenterology, Rabin Medical Center, Tel Aviv University, 49 Jabotinski Street, Petach Tikva 4910000, Israel. nivyaron80@gmail.com
Telephone: +972-3-9377328 Fax: +972-3-9377341
Received: October 3, 2016
Peer-review started: October 8, 2016
First decision: November 29, 2016
Revised: February 17, 2017
Accepted: March 12, 2017
Article in press: March 13, 2017
Published online: April 26, 2017
Processing time: 204 Days and 16.4 Hours
Peer-review started: October 8, 2016
First decision: November 29, 2016
Revised: February 17, 2017
Accepted: March 12, 2017
Article in press: March 13, 2017
Published online: April 26, 2017
Processing time: 204 Days and 16.4 Hours
Core Tip
Core tip: There is a higher mucin expression in intraductal papillary mucinous neoplasms (IPMN) and ductal pancreatic cancer. Mucin expression may be a bad prognostic factor. MUC2, MUC4, MUC5AC and probably MUC1, are expressed in IPMN advanced to ductal adenocarcinoma. These mucins are also bad prognostic factors for ductal adenocarcinoma.